Antares reports Q2 results, including growth in product sales

Antares Pharma reported operating and financial results for the second quarter of 2016, including revenue of $12.2 million and a net loss per share of $0.04, according to a press release.

The company reported revenue of $24.5 million and a net loss of $0.09 per share for the first half of 2016, according to the release. Product sales rose to $8.7 million for the second quarter, for an increase of 49% compared to the same time period in 2015, according to the release.

The quarterly revenues include $3.8 million in Otrexup (methotrexate) sales, $2.9 million generated from the delivery of the sumatriptan injection single-dose auto injectors to Teva Pharmaceutical Industries and $1 million of epinephrine devices to Teva, according to the release.

Antares also announced there was a increase in the number of Otrexup prescriptions by 16% in the second quarter of 2016 compared with the same time period in 2015, and a 9% increase compared with the first quarter of 2016.

Otrexup injection for subcutaneous use is approved in the United states for treating adults with severe recalcitrant psoriasis, severe active rheumatoid arthritis and children with active polyarticular juvenile idiopathic arthritis, according to the release.

Reference: www.antarespharma.com